Effect of Captopril on Progression to Clinical Proteinuria in Patients With Insulin-Dependent Diabetes Mellitus and Microalbuminuria
- 26 January 1994
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 271 (4) , 275-279
- https://doi.org/10.1001/jama.1994.03510280037029
Abstract
Objectives. —To study the effect of angiotensin converting enzyme inhibition on the rate of progression to clinical proteinuria and the rate of change of albumin excretion rates in patients with insulin-dependent diabetes mellitus and persistent microalbuminuria. Design and Setting. —Randomized, double-blind, placebo-controlled clinical trial of 2 years' duration at 12 hospital-based diabetes centers. Patients. —Ninety-two patients with insulin-dependent diabetes mellitus and persistent microalbuminuria but no hypertension. Intervention. —The patients were randomly allocated in blocks of two to receive either captopril, 50 mg, or placebo twice per day. Measurements. —Albumin excretion rate, blood pressure, glycosylated hemoglobin level, and fructosamine level every 3 months; urinary urea nitrogen excretion every 6 months; and glomerular filtration rate every 12 months. Results. —Twelve patients receiving placebo and four receiving captopril progressed to clinical proteinuria, defined as an albumin excretion rate persistently greater than 200 μg/min and at least a 30% increase from baseline (P=.05). The probability of progression to clinical proteinuria was significantly reduced by captopril therapy (P=.03 by log-rank test). Albumin excretion rate rose from a geometric mean (95% confidence interval) of 52 (39 to 68) to 76 (47 to 122) μg/min in the placebo group but fell from 52 (41 to 65) to 41 (28 to 60) μg/min in the captopril group, a significant difference (P<.01). Mean blood pressure was similar at baseline in the two groups and remained unchanged in the placebo group but fell significantly, by 3 to 7 mm Hg, in the captopril group. Glycosylated hemoglobin levels and glomerular filtration rate remained stable in the two groups. Conclusions. —Captopril therapy significantly impeded progression to clinical proteinuria and prevented the increase in albumin excretion rate in nonhypertensive patients with insulin-dependent diabetes mellitus and persistent microalbuminuria. (JAMA. 1994;271:275-279)Keywords
This publication has 25 references indexed in Scilit:
- Short and long term effects of antihypertensive therapy in the diabetic ratKidney International, 1989
- Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy.BMJ, 1989
- Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy.BMJ, 1988
- Effect of antihypertensive treatment on kidney function in diabetic nephropathy.BMJ, 1987
- Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension.Journal of Clinical Investigation, 1986
- Predicting Diabetic Nephropathy in Insulin-Dependent PatientsNew England Journal of Medicine, 1984
- Incipient nephropathy in Type 1 (insulin-dependent) diabetesDiabetologia, 1984
- Long-term antihypertensive treatment inhibiting progression of diabetic nephropathyBMJ, 1982
- Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretionActa Endocrinologica, 1982
- MICROALBUMINURIA AS A PREDICTOR OF CLINICAL NEPHROPATHY IN INSULIN-DEPENDENT DIABETES MELLITUSThe Lancet, 1982